Reoperation for bleeding in an elective cardiac surgical population - Does it affect survival?

Saddiq Mohammad Qazi, Kristian Kandler, Peter Skov Olsen
Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark

Abstract
Introduction: Earlier studies have shown that re-operation for bleeding after cardiac surgery is associated with increased mortality and morbidity in both acute and elective patients. The aim of the study was to assess the effect of re-operation for bleeding on short- and long-term survival and the causes of re-operation on an exclusively elective population.

Methods: This was a single-center, retrospective study conducted at the Department of Cardiothoracic Surgery at Copenhagen University Hospital. Rigshospitalet, Denmark. We included all elective patients undergoing first-time coronary bypass, valve surgery or combinations hereof between January 1998 and February 2014. Data was obtained from the electronic patient records on demographics, cardiological risk profile, blood transfusion and surgical record.

Results: A total of 11813 patients were included in the analysis of whom 626 (5.3%) patients underwent re-operation for bleeding. Patients were divided into two groups; non re-operated (NRO) and re-operated (RO).

Baseline characteristics were comparable. Median survival was lower in the RO group (142 vs 160 months \(P=0.001\)). Morbidity and 30 day mortality was significantly higher in the RO group. Cox-regression analysis showed a significantly increased age-adjusted risk of death in the RO group (HR 1.21 (1.07-1.37), \(P=0.003\)). In 85% of the patients the site of bleeding was found during the re-operation.

Conclusion: We found both short and long-term survival to be lower in the RO group. A surgical cause for re-operation was found in the majority of cases. The study shows the importance of meticulous hemostasis during cardiac surgery.

Materials and methods
Design: This was a single-center retrospective study conducted at the Department of Cardiothoracic Surgery at Rigshospitalet, Copenhagen, Denmark. We included all elective patients undergoing first-time cardiac surgery between January 1998 and February 2014. We included CABG, valve (mitral, aortic and tricuspid) procedures and combinations hereof. Exclusion criteria were age under 18 years, congenital heart disease, non-elective surgery, previous cardiac surgery, more than three procedures, coronary re-implantation (e.g. Bentall procedures), aortic arch surgery and foreign citizens (follow-up not possible). The primary outcome was long-term survival. Secondary outcomes included morbidity and surgical findings during reoperation.

The preoperative and surgical data was obtained from the Patient Analysis and Tracking System (PATS) database (Axis Clinical Software Inc., Portland, USA) containing surgical and cardiological data. Follow-up was conducted via PATS, which automatically collects date of death from the National Patient Registry.

Data on the use of blood products was obtained from...
the local blood bank at our institution. We recorded all red blood cell transfusions (RBCs), thrombocyte pools (from 4 donors) and plasma units within 30 days postoperative. Our transfusion cutoff was 7.25 g/dL during the study period, however in the acute setting of a reoperation for bleeding, the hemoglobin concentration is rarely considered. In these situations, hemodynamics ased by invasive blood pressure monitoring, lactate level development, central venous oxygen saturation and pressure along with cardiac ultrasound performed by a cardiologist.

The resulting composite database was internally validated for duplicates and non-matched patients.

Criteria for reoperation

The decision to reoperate was made by the surgeons on call. At our center we adhere to the Kirklin/Barrat-Boyes criteria for reoperation or on the type of bleeding such as sudden massive bleeding, or haemodynamic instability; reoperation is initiated if drainage output is above 500 mL during the first hour, more than 400 mL during each of the first 2 hours, more than 300 mL during each of the first 3 hours, or more than 1000 mL in total in the first 4 hours.6

Statistics analysis

Continuous data are presented as means ± standard deviations (SD) when normally distributed or median (range) when the distribution is skewed. Continuous variables were compared by Student’s t-test, when normally distributed. Skewed continuous data were analysed using the Mann-Whitney U test. Categorical variables were compared by Pearson’s chi-squared test, and Bonferroni correction for multiple testing. Based on the significant parameters in the univariate analysis, was included in a binary logistic regression model. Excepted from this was two procedures, as to eliminate risk of multicollinearity. In the binary logistic regression analysis, a backwards stepwise model selection was used with the criteria of $P \geq 0.10$ for removal of the covariate from the model. The included variables included a normal distribution.

Survival analysis was performed using Cox proportional hazard analysis adjusted for age and the log rank test.

Differences was considered significant when $P<0.05$. All calculations were done using SPSS 21.0 (IBM, New York, USA).

Results

A total of 12439 patients were included in the analysis, of whom 626 (5.6%) patients underwent reoperation for bleeding. Patients were divided into two groups; non-reoperated (non-RO) and reoperated (RO). The baseline characteristics of the two groups are shown in Table 1. Table 2 shows the character of the procedures.

Our logistic regression model found that diabetes (OR 1.35 (CI 1.02-1.78)), BMI (OR 0.96 (CI 0.94-0.99)) and ECC duration (OR 1.005 (CI 1.003-1.007)) were independently associated with reoperation for bleeding. Age was not found to be independently associated with reoperation for bleeding.

We found a significantly higher 30-day mortality and overall mortality in the RO group (Figure 1). There were significant differences between the two groups on almost all postoperative parameters (Table 3). Furthermore, significantly more transfusions were utilized in the RO group.

Cox-regression analysis showed a significantly increased age-adjusted risk of death in the RO group (HR 1.21 (1.07-1.37), $P=0.003$).

In 258 (41% of all RO patients), patients the surgical findings were given in the database. The bleeding site database was an addition to our PATS database that came late in the study population. In 40 patients (16%) the reason given as “no surgical cause found” or “coagulopathy”, in

| Table 1. Baseline characteristics |
|----------------------------------|
| Patient demographics             |
| -Age (years)                     | 65.8 (+/- 10.5) | 66.9 (+/- 10.9) | 0.007 |
| -Gender (males)                  | 8423 (77%)      | 471 (75%)       | 0.98  |
| -BMI                            | 27.1 (+/- 4.5)  | 26.2 (+/- 4.2)  | 0.001 |
| Hypercholesterolaemia            | 66.9 (+/-10.9)  | 1118 (18.8)     |       |
| Hypertension                     | 5402 (48.3)     | 66 (18.7)       | 0.015 |
| Diabetes, all types              | 4581 (40.9)     | 231 (36.9)      | 0.045 |
| Smoking, active                  | 1800 (16.8)     | 70 (11.2)       | 0.0002|
| Peripheral arterial disease      | 6 (0.6)         | 112 (17.9)      |       |
| Family history of IHD            | 7 (0.6)         | 59 (9.4)        | 0.82  |
| Prior stroke/TCI                 | 102 (0.9)       | 6 (1.0)         | 0.92  |
| NYHA class                       | 1006 (9.0)      | 59 (9.4)        | 0.82  |
| NYHA I                           | 2560 (22.9)     | 140 (22.4)      | 0.72  |
| NYHA III                         | 1179 (10.5)     | 65 (10.4)       | 0.90  |
| NYHA IV                          | 72 (0.6)        | 7 (1.1)         | 0.25  |
| CCS class                        | 1025 (9.2)      | 51 (8.1)        | 0.39  |
| CCS I                            | 2839 (25.4)     | 132 (21.3)      | 0.01  |
| CCS II                           | 1186 (10.6)     | 80 (12.8)       | 0.12  |
| CCS IV                           | 210 (1.9)       | 14 (2.2)        | 0.64  |
| No angina                        | 3302 (29.5)     | 189 (30.2)      | 0.85  |
| Preoperative LVEF                | 0-29%            | 216 (1.9)       | 0.45  |
| 30-49%                           | 700 (6.3)       | 38 (6.1)        | 0.87  |

Abbreviations: BMI, body mass index; MI, myocardial infarction; NYHA, New York Heart Association score; CCS, Canadian Cardiovascular Society grading; LVEF, left ventricular ejection fraction; IHD, ischaemic heart disease; TCI, transient cerebral ischaemia

Baseline characteristics and preoperative data for the two groups is shown in Table 1. Continuous data are presented as mean +/- standard deviation or median (range). Categorical data are presented as number (percentage of total in subgroup). Level of significance after Bonferroni correction is 0.002.
the remaining 218 patients (85%) a surgical bleeding site was found (Table 4).

### Discussion

Undergoing a reoperation for bleeding as well as receiving blood transfusions after cardiac surgery has been shown to be associated with a higher morbidity and mortality in a general cardiac surgery population, which also includes acute and sub-acute cases. This study examined if a reoperation and the associated complications affected survival in a group of elective patients undergoing cardiac surgery. We found a similar pattern with a significantly increased mortality as well as morbidity in patients undergoing reoperation, and a higher requirement of RBC transfusions.

In our study the RO group received five times as many units of RBCs compared to the non-RO group, and there are previous studies to support that this has a detrimental effect on the survival.

Our transfusion cutoff was 7.25 g/dL during the study period, however in the acute setting of a reoperation for bleeding, the hemoglobin concentration is rarely considered. In these situations, hemodynamics assessed by invasive blood pressure monitoring, lactate level development, central venous oxygen saturation and pressure along with cardiac ultrasound performed by a cardiologist was essential in the decision-making for reoperation and transfusions.

Koch et al examined a population of 11,963 isolated CABG patients and found a significantly increased and dose-dependent mortality when RBC transfusion was given (OR = 1.77 for a single RBC-transfusion), and these findings are supported by multiple studies. However all these studies included non-elective patient groups, as opposed to this study.

There is also evidence to support that transfusions can have a detrimental effect on long term survival. However our data foremost shows a rapid decline in survival in the immediate postoperative period in the RO group (Figure 1), a distribution similar to that found in other studies. The increased early mortality is most likely caused by an

### Table 2. Operative data

|                      | Non-reoperated | Reoperated | P value |
|----------------------|----------------|------------|---------|
| **n = 11187**        | **n = 626**    |            |         |
| **Single procedures**|                |            |         |
| CABG                 | 6590           | 313        |         |
| Valve                | 2710           | 173        |         |
| **Single procedures total** | 9300 (83,1%) | 486 (78,7%) | 0.0001 |
| **Double procedures**|                |            |         |
| Valve+CABG           | 1276           | 99         |         |
| Valve + other        | 497            | 37         |         |
| CABG + other         | 114            | 4          |         |
| **Multiple procedures total** | 1887 (16,9%) | 140 (22,3%) | 0.0005 |
| ECC time, min        | 97 (+/- 36)    | 105 (+/- 39) | 0.001 |

Abbreviations: CABG, coronary artery bypass graft; ECC, extracorporeal circulation

Type of elective surgery and the distribution of single and multiple procedures for the two groups is shown.

Continuous data are presented as mean +/- standard deviation or median (range). Categorical data are presented as number (percentage of total in subgroup)

|                      | Non-reoperated | Reoperated | P value |
|----------------------|----------------|------------|---------|
| **Follow-up**        |                |            |         |
| Median survival, months (95% CI) | 160 (154-165) | 142 (125-138) | 0.001 |
| Overall mortality    | 3346 (29.9)    | 261 (41.7) | 0.001 |
| Postoperative complications |            |            |         |
| 30 day mortality     | 253 (2.2)      | 30 (4.8)   | 0.001 |
| 1-year mortality     | 545 (4.9)      | 65 (10.4)  | 0.001 |
| 5-year mortality     | 3214 (28.7)    | 243 (38.9) | 0.001 |
| Myocardial infarction| 168 (1.5)      | 12 (1.9)   | 0.45   |
| Atrial fibrillation  | 4441 (39.7)    | 304 (48.6) | 0.0003 |
| Stroke               | 134 (1.2)      | 17 (2.7)   | 0.005  |
| Deep wound infection | 75 (0.7)       | 15 (2.4)   | 0.001  |
| Renal failure – dialysis | 233 (2.1) | 49 (7.8)  | 0.0001 |
| Multi organ failure  | 98 (0.9)       | 22 (3.5)   | 0.0001 |
| ICU stay, days       | 1.3 (+/- 2.4)  | 2.4 (+/- 4.1) | 0.001 |
| Ventilator >48h      | 393 (3.4)      | 91 (14.0)  | 0.001 |
| Transfusions         |                |            |         |
| RBCs                 | 1.3 (+/- 3.0)  | 8.0 (+/-8.8) | 0.001 |
| Thrombocytes         | 0.2 (+/- 0.8)  | 2.2 (+/-2.8) | 0.001 |
| Plasma               | 0.4 (+/- 2.4)  | 5.0 (+/-7.1) | 0.001 |

Abbreviations: CI, confidence interval; RBCs, red blood cells

Mortality, major complications and number of transfusions is presented for the two groups. Continuous data are presented as mean +/- standard deviation or median (range). Categorical data are presented as number (percentage of total in subgroup)

Figure 1. Age adjusted Cox-regression survival analysis is shown for the study period. Individual cross-marks shows death of a patient in the respective groups.
increase in early postoperative complications, as can be seen in Table 3. This is reflected in the survival curve, as the RO group has an initial drop, in the long term our curves are similar and seems parallel. This could imply an immediate effect of reoperation and complications, without any detrimental effects on the long term.

Although the relationship between transfusions and mortality is well-documented in retrospective studies, the link has been somewhat elusive in randomised controlled studies. Patel et al in their meta-analysis did not find a link between a liberal transfusion-strategy and increased mortality in a population of patients undergoing cardiac surgery.15 The discrepancies between prospective and retrospective studies could reflect that the relationship between transfusions and survival is heavily confounded, and difficult to adjust for, as multiple transfusions are expected to be given to anemic, bleeding and co-morbid patients, all of which could affect survival.13 The later “The Transfusion Requirements in Cardiac Surgery (TRICS)” randomized trials did not find significant differences between a liberal or restrictive transfusions in mortality outcomes, even at 6 months.16 This makes interpretations of the significant and considerable effects of transfusions on mortality in retrospective studies even more obscure, and could imply shortcomings of statistical models to exclude the effect of confounding.

The reoperation for bleeding has, in itself, been associated with an increase in mortality. Ranucci et al reported twice the mortality compared to the mortality predicted by EUROscore.7 Moulton et al reported an odds ratio of 4.4 on mortality in a low-risk elective CABG-population, when reoperation was needed.17 In addition to a significantly higher mortality, our data shows an increased incidence of acute kidney injury, infections, stroke and atrial fibrillation in the RO group. This could reflect the additional surgical stress, inflammation, possible anemia, hypoxia, prolonged ventilation and exposure to microbes associated with reoperation. The long-term mortality in this study was comparable to a previous study with up to 30 years follow-up.18

Both our populations had similar pre-operative risk profiles, however there was a large difference in the postoperative outcomes between the two groups. Furthermore, the findings during reoperation were predominantly surgical bleeding (83.4%) and to lesser extent coagulopathy (16.4%), which is similar to earlier reports.19 This points towards a predominantly insufficient surgical haemostasis at the primary operation. However, the initial source of bleeding which causes the need for reoperation can be difficult to assess due to factors such as removal of steelwires, bleeding because of re-opening and new onset of coagulopathy. Our study is conducted at one center, on a very large number of patients, with complete and long-term follow-up.

Our study is primarily limited by its retrospective design. Our inclusion period spans more than a decade; however, we do not believe this has affected our outcome. A propensity match study was considered but advised against by our statistician. We did not have information on preoperative anticoagulants and other drugs. However, during the study period it was the policy of our center to stop treatment with acetylsalicylic acid and clopidogrel for five days prior to surgery, and warfarin three days prior to elective surgery.

**Conclusion**

In this study we found a mortality hazard ratio of 1.21 in patients undergoing reoperation for bleeding after elective cardiac surgery. The RO group had a significantly higher number of complications, translating into lower short and long-term survival. As a surgical cause for reoperation was found in the majority of cases, stressing the need for careful haemostasis during the operation to avoid a possible initiating event for other complications.

**Competing interest**

The authors have no competing interests.

**Ethical approval**

Due to the retrospective nature of this study, an ethical and legal approval for data collection was approved by the Danish Patient Safety Authority, approval number: 2012-56-0004.

**Funding**

Due to the retrospective nature of this study, no funding was needed.

**References**

1. Mehta RH, Sheng S, O’Brien SM, Grover FL, Gammie JS, Ferguson TB, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. *Circ Cardiovasc Qual Outcomes*. 2009;2(6):583-590. doi:10.1161/CIRCOUTCOMES.109.858811

2. Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ, et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. *Eur J Cardiothorac Surg*. J Cardiovasc Thorac Res, 2021, 13(3), 198-202 | 201
3. Bhaskar B, Dullhunty J, Mullany DV, Fraser JE. Impact of blood product transfusion on short and long-term survival after cardiac surgery: more evidence. Ann Thorac Surg. 2012;94(2):460–467. doi:10.1016/j.athoracsur.2012.04.005

4. Berger JS, Fye CR, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52(21):1693–1701. doi:10.1016/j.jacc.2008.08.031

5. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15(6):816–822; discussion 822–813. doi:10.1016/s1010-7940(99)00106-2

6. Kouchoukos N, Blackstone E, Kirklin J. Kirklin/Barratt-Boyes: Cardiac Surgery. 4th ed. Elsevier; 2013. p. 2256.

7. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A. Surgical reexploration after cardiac operations: why a worse outcome? Ann Thorac Surg. 2008;86(5):1557–1562. doi:10.1016/j.athoracsur.2008.07.114

8. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608–1616. doi:10.1097/01.ccm.0000217920.48559.d8

9. Paone G, Likosky DS, Brewer R, Theuerer PF, Bell GF, Cogan CM, et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. Ann Thorac Surg. 2014;97(1):87–93; discussion 93–84. doi:10.1016/j.athoracsur.2013.07.020

10. Möhnle P, Snyder-Ramos SA, Miao Y, Kulier A, Böttiger BW, Levin J, et al. Postoperative red blood cell transfusion and morbidity outcome in uncomplicated cardiac surgery patients. Intensive Care Med. 2011;37(1):97–109. doi:10.1007/s00134-010-2017-z

11. Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006;81(5):1650–1657. doi:10.1016/j.athoracsur.2005.12.037

12. Stone GW, Clayton TC, Mehran R, Dangas G, Parise H, Fahy M, et al. Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUTY) trial. Am Heart J. 2012;163(3):522–529. doi:10.1016/j.ahj.2011.11.016

13. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissere G. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg. 2013;96(2):478–485. doi:10.1016/j.athoracsur.2013.03.015

14. Jakobsen CJ, Ryhammer PK, Tang M, Andreasen JI, Mortensen PE. Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients. Eur J Cardiothorac Surg. 2012;42(1):114–120. doi:10.1093/ejcts/ezr242

15. Patel NN, Avlonitis VS, Jones HE, Reeves BC, Sterne JA, Murphy GI. Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. Lancet Haematol. 2015;2(12):e543–553. doi:10.1016/s2352-3026(15)00198-2

16. Mazer CD, Whitlock RP, Fergusson DA, Belley-Cote E, Connolly K, Khanykin B, et al. Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. N Engl J Med. 2018;379(13):1224–1233. doi:10.1056/NEJMoa1808561

17. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111(5):1037–1046. doi:10.1016/s0022-5223(96)70380-x

18. Adelborg K, Horváth-Puhó E, Schmidt M, Munch T, Pedersen L, Nielsen PH, et al. Thirty-year mortality after coronary artery bypass graft surgery: a Danish nationwide population-based cohort study. Circ Cardiovasc Qual Outcomes. 2017;10(5):e002708. doi:10.1161/circoutcomes.116.002708

19. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL, Blackstone EH, et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91(6):1780–1790. doi:10.1016/j.athoracsur.2011.03.105